EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic Modifications in Osteosarcoma: Mechanisms and Therapeutic Strategies

Maria A Katsianou iD, Dimitrios Andreou, Penelope Korkolopoulou iD, Eleni-Kyriaki Vetsika iD, Christina Piperi iD

Life · 28.07.2025 · 15 (8) · 1202

DOI: 10.3390/life15081202 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 28.07.2025. Verfasst von Maria A Katsianou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS), the most common primary bone cancer of mesenchymal origin in children and young adolescents, remains a challenge due to metastasis and resistance to chemotherapy. It displays severe aneuploidy and a high mutation frequency which drive tumor initiation and progression; however, recent studies have highlighted the role of epigenetic modifications as a key driver of OS pathogenesis, independent of genetic mutations. DNA and RNA methylation, histone modifications and non-coding RNAs are among the major epigenetic modifications which can modulate the expression of oncogenes. Abnormal activity of these mechanisms contributes to gene dysregulation, metastasis and immune evasion. Therapeutic targeting against these epigenetic mechanisms, including inhibitors of DNA and RNA methylation as well as regulators of RNA modifications, can enhance tumor suppressor gene activity. In this review, we examine recent studies elucidating the role of epigenetic regulation in OS pathogenesis and discuss emerging drugs or interventions with potential clinical utility. Understanding of tumor- specific epigenetic alterations, coupled with innovative therapeutic strategies and AI-driven biomarker discovery, could pave the way for personalized therapies based on the molecular profile of each tumor and improve the management of patients with OS.

Schlagwörter

Stichwörter der Autor:innen

AI-based therapiesDNA methylationbiomarkerepigenetic mechanismsnon-coding RNAsosteosarcomatherapeutic targets

Autor:innen und Institutionen

  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Maria A Katsianou, Penelope Korkolopoulou, Eleni-Kyriaki Vetsika, Christina Piperi

Zitieren

APA

Katsianou, M. A., Andreou, D., Korkolopoulou, P., Vetsika, E. K., & Piperi, C. (2025). Epigenetic Modifications in Osteosarcoma: Mechanisms and Therapeutic Strategies. Life, 15(8), 1202. https://doi.org/10.3390/life15081202

Vancouver

Katsianou MA, Andreou D, Korkolopoulou P, Vetsika EK, Piperi C. Epigenetic Modifications in Osteosarcoma: Mechanisms and Therapeutic Strategies. Life. 2025;15(8):1202. doi:10.3390/life15081202

BibTeX
@article{Katsianou2025,
  author = {Katsianou, Maria A and Andreou, Dimitrios and Korkolopoulou, Penelope and Vetsika, Eleni-Kyriaki and Piperi, Christina},
  title = {Epigenetic Modifications in Osteosarcoma: Mechanisms and Therapeutic Strategies},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {1202},
  doi = {10.3390/life15081202}
}
Kostenlos starten →